We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
This activity is no longer available for CME credits.
This activity is intended for physicians, APPs, Nurses, pharmacists and multi-disciplinary team members who are engaged in the care of patients with inflammatory bowel disease (IBD) in primary care, managed care organizations, ambulatory care, and hospital settings.
After completing this activity, the participant should be better able to:
• Discuss treatments for patients with IBD, taking into consideration disease history, disease severity, and patient preference
• Demonstrate shared decision-making and co-production models that facilitate open provider/patient dialogue
• Optimize communication methods and empower patients
• Recognize the impact of IBD on patients and
• Apply evidence-based IBD pathways in patient education and shared decision-making
• Implement co-productive patient-provider strategies including key learnings from clinical trial results and emerging research in IBD into clinical practice to improve overall patient outcomes
• Identify areas of miscommunication and engage patients on management expectations for Crohn’s and UC
Miguel Regueiro, MD, Cleveland Clinic
Katie Falloon, MD, Cleveland Clinic
Shuba Bhat, PharmD, Cleveland Clinic
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
Miguel Regueiro, M.D. receives the following financial support:
Unrestricted Educational Grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly
Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS
CME Companies: CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGlobal
Royalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn’s and Colitis Foundation as Editor-in-Chief, CC360
Katie Fallon, MD receives the following financial support:
Grants and Research Support: Crohn’s and Colitis Foundation Clinical Research Alliance Award
Advisory Boards: GI Fellow Advisory Board for Janssen
ShubhaBhat, PharmD receives the following financial support:
Speakers Bureau/Honoraria for non-CME: Eli Lilly, Prometheus Lab
Consultant/Advisory Board: AbbVie, Bristol-Myers Squibb, Prometheus Lab, Boehringer Ingelheim, Pfizer
The PIM planners and others have nothing to disclose. The Crohns & Colitis Foundation planners and others have nothing to disclose
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Crohn’s & Colitis Foundation Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-23-307-H01-P)
Type of Activity: Application
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is no longer available for CME credits.
This activity is intended for physicians, APPs, Nurses, pharmacists and multi-disciplinary team members who are engaged in the care of patients with inflammatory bowel disease (IBD) in primary care, managed care organizations, ambulatory care, and hospital settings.
After completing this activity, the participant should be better able to:
• Discuss treatments for patients with IBD, taking into consideration disease history, disease severity, and patient preference
• Demonstrate shared decision-making and co-production models that facilitate open provider/patient dialogue
• Optimize communication methods and empower patients
• Recognize the impact of IBD on patients and
• Apply evidence-based IBD pathways in patient education and shared decision-making
• Implement co-productive patient-provider strategies including key learnings from clinical trial results and emerging research in IBD into clinical practice to improve overall patient outcomes
• Identify areas of miscommunication and engage patients on management expectations for Crohn’s and UC
Miguel Regueiro, MD, Cleveland Clinic
Katie Falloon, MD, Cleveland Clinic
Shuba Bhat, PharmD, Cleveland Clinic
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
Miguel Regueiro, M.D. receives the following financial support:
Unrestricted Educational Grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly
Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS
CME Companies: CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGlobal
Royalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn’s and Colitis Foundation as Editor-in-Chief, CC360
Katie Fallon, MD receives the following financial support:
Grants and Research Support: Crohn’s and Colitis Foundation Clinical Research Alliance Award
Advisory Boards: GI Fellow Advisory Board for Janssen
ShubhaBhat, PharmD receives the following financial support:
Speakers Bureau/Honoraria for non-CME: Eli Lilly, Prometheus Lab
Consultant/Advisory Board: AbbVie, Bristol-Myers Squibb, Prometheus Lab, Boehringer Ingelheim, Pfizer
The PIM planners and others have nothing to disclose. The Crohns & Colitis Foundation planners and others have nothing to disclose
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Crohn’s & Colitis Foundation Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-23-307-H01-P)
Type of Activity: Application
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Stay current with the best on medical education
